The December 2022 issue of IEEE Spectrum is here!

Close bar

Photoluminescent Nanoparticles Kill Cancer

Researchers discover novel nanoparticle that when triggered by X-rays can treat tumor tissue

2 min read
Photoluminescent Nanoparticles Kill Cancer
This figure from the paper shows the X-ray destruction of human breast cancer cells using Cu-Cy particles. The images show the live cancer cells stained green and the dead cells stained red
Images: University of Texas at Arlington

In a case of serendipity, researchers at the University of Texas at Arlington started out trying to develop new security-related radiation detection and stumbled upon a potential breakthrough in cancer treatment.

In the research, which will be published in the August edition of the Journal of Biomedical Nanotechnology (“A New X-Ray Activated Nanoparticle Photosensitizer for Cancer Treatment”), Wei Chen, professor of physics at the UT Arlington, was exposing copper-cysteamine (Cu-Cy) nanoparticles to X-rays when he noticed an unusual luminescence over a time-lapse exposure. When he investigated the cause of the Cu-Cy nanoparticle luminescence, he realized that the particles were losing energy as they emitted singlet oxygen, a toxic byproduct that also happens to be used to in photodynamic cancer therapy to damage cancer cells.

“This new idea is simpler and better than previous photodynamic therapy methods. You don’t need as many steps. This material alone can do the job,” Chen, who is also leading federally-funded cancer research, said in a press release. “It is the most promising thing we have found in these cancer studies and we’ve been looking at this for a long time.”

Photodynamic therapy (PDT) is a technique in which some photosensitizer is introduced into tumor tissue. When exposed to light, the photosensizer produces singlet oxygen that kills the cancer cells. Two years ago, this blog covered research from Rice University related to a similar PDT technique in which gold nanoparticles were introduced near a tumor and then subjected to light. This light exposure to the cluster of nanoparticles created bubbles that burst, temporarily ripping open small pores in the cell membranes that allow drugs to penetrate. 

The problem with PDT techniques is that the light cannot penetrate very far into human tissue to activate the nanoparticles. Chen and his colleagues have discovered that Cu-Cy the nanoparticle's sensitivity to X-rays and the ability of X-rays to penetrate deeply into tissue means that the tumor can be deep inside tissue and still be effective. Another advantage of the Cu-Cy nanoparticle in combination with the X-rays is that no other photosensitizer needs to be used, making it convenient, efficient and cost-effective, according to the researchers.

Like some of the “theranostic” nanoparticles that are being developed, in which both therapeutic and diagnostic functions are combined into one nanoparticle, the Cu-Cy nanoparticle can serve both as treatment for cancer as well as for cell imaging.

In experiments carried out thus far, Chen and his team have used the Cu-Cy nanoparticle and X-ray combination to treat a tumor. The results over a 13-day period showed that the tumor had not grown at all with the treatment while a tumor that had not been treated grew three times in size.

The UT Arlington has applied for a patent on the technology. Meanwhile Chen and his team are working on ways to shrink the size of the Cu-Cy nanoparticles, which currently are around 250 nanometers, so that the tumor tissue can more easily absorb them. If they can reduce the nanoparticles down to dimensions below 200nm, this should improve cell uptake. Ideally, they would like to bring those dimensions down to around 50 to 100nm.

The Conversation (0)

Are You Ready for Workplace Brain Scanning?

Extracting and using brain data will make workers happier and more productive, backers say

11 min read
Vertical
A photo collage showing a man wearing a eeg headset while looking at a computer screen.
Nadia Radic
DarkGray

Get ready: Neurotechnology is coming to the workplace. Neural sensors are now reliable and affordable enough to support commercial pilot projects that extract productivity-enhancing data from workers’ brains. These projects aren’t confined to specialized workplaces; they’re also happening in offices, factories, farms, and airports. The companies and people behind these neurotech devices are certain that they will improve our lives. But there are serious questions about whether work should be organized around certain functions of the brain, rather than the person as a whole.

To be clear, the kind of neurotech that’s currently available is nowhere close to reading minds. Sensors detect electrical activity across different areas of the brain, and the patterns in that activity can be broadly correlated with different feelings or physiological responses, such as stress, focus, or a reaction to external stimuli. These data can be exploited to make workers more efficient—and, proponents of the technology say, to make them happier. Two of the most interesting innovators in this field are the Israel-based startup InnerEye, which aims to give workers superhuman abilities, and Emotiv, a Silicon Valley neurotech company that’s bringing a brain-tracking wearable to office workers, including those working remotely.

Keep Reading ↓Show less
{"imageShortcodeIds":[]}